



Legacy Healthcare Appoints Peter Nicholson to Board of Directors

Epalinges, Switzerland, 1 December 2024 - - Legacy Healthcare, a Swiss-based biotechnology company developing first-in-class botanical drugs for human health, today announced that it had appointed Peter Nicholson to serve on its Board of Directors as an independent board member.

“Peter’s track record of success, his industry experience, network and education make him an ideal fit for Legacy Healthcare,” commented Saad Harti, Chairman & CEO of Legacy Healthcare. “We are excited to have him join our Board at this critical juncture, as we advance the filings of our first botanical drug CINAINU focused on treating alopecia areata in Europe, the US and Japan.”

A San Francisco, California native, Mr. Nicholson currently resides in Switzerland and is Managing Director of ALTEKA, a boutique strategic advisory firm serving the biopharmaceutical industry. He was previously Senior Vice President of Global Business Development for Dermavant Sciences (Organon). Before that, he served as Vice President of Strategy and Business Development for Galderma. He held similar roles for Mentor (J&J) and Inamed (Allergan). He was co-founder and CEO of Blue Heron Bio (Eurofins Genomics). While working at Amgen, he worked in product development and then joined the product licensing team, responsible for creating the company’s corporate venture capital program.

“I am pleased to have the opportunity to support Legacy Healthcare on its mission to address serious medical conditions with botanical drugs,” commented Peter Nicholson. “Because of the pleiotropic activity of plant-based pharmaceutical grade extracts and their strong safety profile, botanical drugs represent a compelling opportunity to provide doctors with a new choice to advance patients care, aligned with what the world needs today.”

About Legacy Healthcare

Legacy Healthcare is a Swiss-based biopharmaceutical company focused on leveraging the pleiotropic activity and strong safety profile of plants to develop prescription botanical drugs that address serious medical conditions. The company’s first product candidate, CINAINU, has demonstrated strong safety and efficacy in a phase 2/3 study involving patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it, especially children.

For more information please visit www.legacyhealthcare.ch

Inquiries: contact@leagacyhealthcare.ch;